title: Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data.
abstract: Neu-glycolyl (NeuGc)-containing gangliosides are attractive targets for immunotherapy with anti-idiotype mAbs, because these glycolipids are not normal components of the cytoplasmic membrane in humans, but their expression has been demonstrated in several human malignant tumors. Racotumomab is an anti-idiotype mAb specific to P3 mAb, an antibody which reacts to NeuGc-containing gangliosides, sulfatides, and other antigens expressed in tumors. Preparations containing racotumomab were able to induce a strong anti-metastatic effect in tumor-bearing mice. Different Phase I clinical trials have been conducted in patients with advanced melanoma, breast cancer, and lung cancer. The results of these clinical trials demonstrated the low toxicity and the high immunogenicity of this vaccine. The induced antibodies recognized and directly killed tumor cells expressing NeuGcGM3. A Phase II/III multicenter, controlled, randomized, double blind clinical trial was conducted to evaluate the effect of aluminum hydroxide-precipitated racotumomab vaccine in overall survival in patients with advanced non-small cell lung cancer. The clinical results of this study showed a significant clinical benefit in the patients who were treated with the anti-idiotype vaccine.
authors.affiliation: Center of Molecular Immunology Havana, Cuba.
authors.forename: Ana M
authors.initials: AM
authors.lastname: Vázquez
authors.forename: Ana M
authors.initials: AM
authors.lastname: Hernández
authors.forename: Amparo
authors.initials: A
authors.lastname: Macías
authors.forename: Enrique
authors.initials: E
authors.lastname: Montero
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Gómez
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Alonso
authors.forename: Mariano R
authors.initials: MR
authors.lastname: Gabri
authors.forename: Roberto E
authors.initials: RE
authors.lastname: Gómez
keywords: anti-idiotype vaccine; cancer; immunotherapy